RxDoctor Payments Data

Julie Perry, APRN

Psychiatric/Mental Health · Lexington, KYNPI 1194949156

Payments from drug & device makers

$562in general payments, 2019–2025

Across 11 payments — averaging $51.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$138
  • Mylan Specialty L.p.$121
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$117
  • AbbVie$49
  • Otsuka America Pharmaceutical, Inc.$48
  • Gilead$37
  • plus $52 from 3 others

What the payments were for

  • Food & beverage$562100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$562 in reported general payments places this provider in the 40th percentile of 946 psychiatric/mental health providers in Kentucky.

See all psychiatric/mental health providers in Kentucky

Medicare billing

Part B allowed, 2024
$2,057
Medicare patients
17
Services billed
34

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate17$58,474
Risperdal ConstaRisperidone Microspheres12$27,730
JardianceEmpagliflozin27$27,025
OzempicSemaglutide28$26,906
RexultiBrexpiprazole11$15,907
MounjaroTirzepatide16$14,225
TrulicityDulaglutide11$13,275
XareltoRivaroxaban14$8,130
Fluphenazine Hcl26$6,248
Lurasidone Hcl22$6,227
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog30$5,424
Divalproex Sodium99$4,706
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl74$3,869
Gabapentin192$2,802
Varenicline Tartrate12$2,651

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Rexulti$48$15,90711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 946 psychiatric/mental health providers in Kentucky.

Other psychiatric/mental health in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →